^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MYC positive

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
16d
Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma. (PubMed, Cancer Med)
Our results confirm that genomic alteration differs significantly between EBV-posDLBCL and EBV-negDLBCL, and reveal new genetic alterations in EBV-posDLBCL. The positive correlation of c-MET and PD-L1/c-Myc expression may be involved in the pathogenesis of EBV-posDLBCL, which is should be explored prospectively in trials involving MET-directed therapies.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • JAK2 (Janus kinase 2) • PIM1 (Pim-1 Proto-Oncogene) • DCAF8L1 (DDB1 And CUL4 Associated Factor 8 Like 1)
|
PD-L1 expression • MET expression • MYC expression • MYC positive • MYC negative
17d
Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. (PubMed, Signal Transduct Target Ther)
Significantly, targeting CPT1A enhances immune checkpoint blockade-induced anti-tumor immunity and tumoral ferroptosis in tumor-bearing mice. The results illustrate the potential of a mechanism-guided therapeutic strategy by targeting a metabolic vulnerability in the ferroptosis of CSCs to improve the efficacy of lung cancer immunotherapy.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • CPT1A (Carnitine Palmitoyltransferase 1A)
|
MYC expression • MYC positive
1m
C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer. (PubMed, World J Surg Oncol)
Our study provides insights into the clinical aspects of Myc family members in surgically resected SCLC tumors. Notably, besides showing that positivity of Myc family members varies across the patients, we also reveal that C-Myc protein expression independently correlates with worse survival outcomes. Further studies are warranted to investigate the role of Myc family members as potential prognostic and predictive markers in this hard-to-treat disease.
Clinical data • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • YAP1 (Yes associated protein 1) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
|
MYC expression • MYC positive • MYC negative
1m
A Phase I study of PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
P1, N=54, Terminated, Pimera Australia Pty Ltd | Recruiting --> Terminated
Trial termination • Metastases
|
MYC positive
|
PMR-116
1m
RNASeq Analysis for Accurate Identification of Fusion Partners in Tumor Specific Translocations Detected by Standard FISH Probes in Hematologic Malignancies. (PubMed, Clin Pathol)
These are 3 cases in a series of several other concordant results, nevertheless, elucidate limitations when interpreting FISH results in clinical applications, particularly when other genes are included in probe design. In addition, when the observed FISH signals are atypical, this study illustrates the necessity to perform complementary laboratory assays, such as NGS and/or RNASeq, to accurately identify fusion genes in tumorigenic translocations.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor) • MEF2D (Myocyte Enhancer Factor 2D) • PVT1 (Pvt1 Oncogene) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
FGFR3 fusion • MYC positive • FGFR3 positive • MEF2D-CSF1R fusion
2ms
Reciprocal regulation of lncRNA MEF and c-Myc drives colorectal cancer tumorigenesis. (PubMed, Neoplasia)
Further, correlations exist between MEF, c-Myc, and hnRNPK suggesting the MEF-c-Myc positive feedback loop is active in patients. Together these data demonstrate that MEF is a pivotal partner of the c-Myc network and propose MEF as a valuable therapeutic target for colorectal cancer.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K)
|
MYC expression • MYC positive
2ms
Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning. (PubMed, Diagn Pathol)
We conclude that proportion of positive stains can be regressed using attention-based multiple instance learning, that these models generalize well to whole slide images, and that our models can provide non-inferior stratification of progression-free survival outcomes.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 positive • MYC positive
2ms
USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. (PubMed, Cell Death Dis)
Additionally, upregulation of USP43 protein in BLCA increased the chance of interaction with c-Myc and interfered with FBXW7 access and degradation of c-Myc. These findings suggest that USP43 is a potential therapeutic target for indirectly targeting glycolytic metabolism and the c-Myc oncoprotein consequently enhancing the efficacy of bladder cancer treatment.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
|
MYC positive
3ms
Clinical study of mature B-cell lymphoma in 11 children with chromosome 11 long-arm abnormalities (PubMed, Zhonghua Xue Ye Xue Za Zhi)
The incidence of MBCL with 11q abnormalities in children is low, clinical symptoms are mild, and progression is slow. The absence of MYC, BCL2, BCL6 rearrangements, C-MYC negative and 11q abnormalities on FISH is an important diagnostic indicator, and reducing the intensity of chemotherapy can improve prognosis.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC positive • MYC negative
4ms
Targeted DNA Damage Boost with Loncastuximab Tesirine in Combination with PARP Inhibitors in Diffuse Large B-Cell Lymphoma (ASH 2023)
Similar results were obtained by combining Talazoparib and different PARP inhibitors with the alkylating agent cisplatin, indicating a class effect. Importantly, PBMC-derived T cells from healthy donors did not show any sign of DNA damage accumulation upon exposure to Lonca, Talazoparib and the combination. These data provide the rationale for future therapeutic strategies based on selective induction of DNA damage in neoplastic B cells in combination with DDR inhibition in aggressive MYC-positive B cell lymphoma.
Combination therapy • BRCA Biomarker • PARP Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BRCA (Breast cancer early onset) • AURKA (Aurora kinase A) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • H2BC8 (H2B Clustered Histone 8)
|
BRCA2 mutation • CD19 positive • MYC rearrangement + BCL2 rearrangement • MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement • MYC positive • BRCA mutation • PARP1 overexpression
|
cisplatin • Talzenna (talazoparib) • Zynlonta (loncastuximab tesirine-lpyl)
4ms
Molecular and clinicopathological features of granzyme B-negative extranodal NK/T-cell lymphoma. (PubMed, Hum Pathol)
In conclusion, GZMB expression is highly heterogeneous in ENKTLs and is associated with the activation of the JAK-STAT3 pathway and higher MYC expression. GZMB-negative ENKTLs correlate with an advanced clinical stage, suggesting the potential utility of GZMB immunohistochemistry as a biomarker of ENKTL.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • GZMB (Granzyme B) • PRF1 (Perforin 1) • TRG (T Cell Receptor Gamma Locus)
|
MYC expression • MYC positive • MYC negative • GZMB negative
5ms
Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study (ASH 2023)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy is the standard first-line treatment of DLBCL...Previous study has showed that ibrutinib combined with R-CHOP had improved event free survival (EFS) compared with placebo plus R-CHOP in non-GCB DLBCL patients with BCL2 and MYC co-expression (Johnson et al., Blood 2019)...Conclusions At the time of data cut-off 30 Jun 2023, 6 cycles of zanubrutinib combined with R-CHOP regimen was well tolerated and showed a promising response result in untreated non-GCB double-expression DLBCL patients. The study is ongoing and further results will be continuously released.
Clinical • P2 data • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression • BCL2 expression + MYC expression • BCL2 positive • MYC positive • MYC expression + BCL2 expression
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • vincristine • prednisone
5ms
Cooperative Networks between MYC and XPO1 Associated with Decreased T-Cell Presence and a Depleted Tumor Microenvironment May be Addressed By the Synergistic Combination of AZD4573 and Selinexor (ASH 2023)
Our results support that the cooperation between MYC and XPO1 is associated with T-cell reductions characteristic of a Depleted or Cold TME, a key issue for CAR-T success. We applied the targeted therapies AZD4573 and Selinexor vs. cell line models to address this pathway, with both displaying anti-tumor effects as single agents.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TNFAIP3 (TNF Alpha Induced Protein 3) • XPO1 (Exportin 1) • CDK9 (Cyclin Dependent Kinase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
MYC expression • MYC positive
|
Xpovio (selinexor) • AZD4573
5ms
Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma (ASH 2023)
Ibrutinib demonstrated significant efficacy with manageable toxicities in previously untreated patients with high-risk smoldering MCL.
P2 data
|
TP53 (Tumor protein P53) • KMT2D (Lysine Methyltransferase 2D) • BIRC3 (Baculoviral IAP repeat containing 3)
|
TP53 mutation • TP53 wild-type • KMT2D mutation • MYC positive
|
Imbruvica (ibrutinib)
5ms
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2026
Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive
|
Imbruvica (ibrutinib)
6ms
Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma. (PubMed, J Clin Pathol)
Our results provide clinical insights into the diagnostic, prognostic and predictive significance of SCLC molecular subtype classifications.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
|
MYC expression • DLL3 expression • MYC positive
6ms
Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers. (PubMed, Front Oncol)
The main objective of this study was to assess the application of the immunohistochemistry- and interphase fluorescence in situ hybridization (FISH)-based molecular markers in the diagnosis of DLBCL and its prognostic value in patients treated with rituximab-based immunochemotherapy...We did not find any difference in survival by GCB vs. non-GCB subtypes. These findings may improve prognostication in DLBCL and can contribute to designing further research in the area.
Retrospective data • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
MYC translocation • MYC positive • BCL6 translocation • IRF4 expression • BCL2 translocation
|
Rituxan (rituximab)
6ms
From the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. (PubMed, Ann Diagn Pathol)
Based on our literature review, and is shown in this case, sporadic BL in adults shows some differences with the classic description of BL in children. We also discuss the differential diagnosis of BL.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • CD22 (CD22 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAX (Integrin Subunit Alpha X) • SOX11 (SRY-Box Transcription Factor 11) • SPN (Sialophorin) • FCER2 (Fc Fragment Of IgE Receptor II)
|
MYC positive • SOX11 expression
6ms
ESRRB inhibits the TGF-β signaling pathway to drive cell proliferation in cervical cancer. (PubMed, Cancer Res)
In turn, MYC transactivated ESRRB and upregulated SMAD7, thus forming a positive feedback loop with ESRRB. Together, these findings identify the tumor promoting function of ESRRB in cervical cancer and reveal a mechanism by which ESRRB stimulates cell proliferation to promote cancer progression.
Journal
|
CCNA2 (Cyclin A2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SMAD7 (SMAD Family Member 7) • SMAD2 (SMAD Family Member 2) • ESRRB (Estrogen Related Receptor Beta)
|
MYC positive
7ms
PRIMARY CARDIAC DIFFUSE LARGE B-CELL LYMPHOMA: A CASE REPORT OF A DOUBLE-EXPRESSION LYMPHOMA (CHEST 2023)
Cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab can be used in the chemotherapy regimen. This is a case of primary cardiac lymphoma (PCL) that encases the SVC and the aorta. PCL is a rare disease that can present with a variety of nonspecific cardiorespiratory symptoms. The case demonstrates that PCL can occur in immunocompetent individuals.
Clinical • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
MYC positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine
7ms
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive
|
Imbruvica (ibrutinib)
8ms
A B-Wildering Case of Gastrointestinal Bleeding (ACG 2023)
Case Description/ A 63-year-old male with a history of coronary artery disease, on aspirin and clopidogrel, presented to the advanced endoscopy clinic for evaluation of GI bleeding with associated anemia...Numerous mitotic figures and apoptotic debris were also noted. (c) The large atypical lymphocytes express CD20 (10x objective) staining, consistent with B cell origin.
Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 expression • BCL2 positive • MYC positive
|
Cologuard®
8ms
Burkitt Lymphoma and Sclerosing Mesenteritis: Case Report (ACG 2023)
Decision was made to initiate EPOCH + Rituximab for treatment and to not pursue the full diagnostic workup of ScM. The patient would receive an alternative form of treatment for ScM of cyclophosphamide already in the EPOCH...This case helps support the theory of ScM being a paraneoplastic syndrome and a sign of underlying malignancies. Currently, there is no uniform recognized therapy, rather the whole clinical picture should be analyzed when determining the best treatment course of action for the patient.
Clinical • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • SDC1 (Syndecan 1) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD20 positive • BCL6 rearrangement • BCL2 rearrangement • MYC positive
|
Rituxan (rituximab) • cyclophosphamide
8ms
MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma. (PubMed, Br J Haematol)
Of these six genes, de novo CTP synthesis pathway enzyme CTPS1 whose inhibitor (STP938) is already in clinical trials for relapsed/refractory lymphomas (NCT05463263) has the highest regression coefficient. Additionally, MYC positively regulates CTPS1 expression, and TP53-aberrant and ibrutinib-resistant MCL cells also rely on cytidine metabolism. Furthermore, besides the obvious decreased CTP pool caused by CTPS1 deficiency, CTPS1 inhibition may also induce immune-related responses via activating dsDNA-cGAS-STING pathway, which plays a crucial role in impeding tumour growth in MCL patients.
Journal
|
TP53 (Tumor protein P53) • CTPS1 (CTP Synthase 1)
|
TP53 expression • MYC positive
|
Imbruvica (ibrutinib) • STP938
8ms
An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. (PubMed, Cancer Commun (Lond))
Our study uncovers a precise mechanism that LINC00665 sustains BCa LN metastasis by inducing a RAB27B-HGF-c-Myc positive feedback loop between BCa cells and fibroblasts, suggesting that LINC00665 could be a promising therapeutic target for patients with LN metastatic BCa.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665)
|
MYC positive
9ms
IMMUNOHISTOCHEMICAL STUDY OF MYC ONCOGENE EXPRESSION IN COLORECTAL ADENOCARCINOMAS AND CORRELATION WITH CELLULAR COMPONENTS OF ADAPTIVE IMMUNITY IN THE TUMOR MICROENVIRONMENT (UEGW 2023)
In patients with colorectal adenocarcinoma, increased MYC expression by neoplastic cells is associated with increased densities of adaptive immune cells in the tumor microenvironment. In addition, it is associated with a favorable prognosis, possibly through a more effective antitumor immune response. Consequently, the expression of MYC might be a useful predicting indicator of anti-tumor immunity status and patient's prognosis.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
MYC expression • MYC positive
10ms
The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development. (PubMed, J Immunother Cancer)
Our work revealed for the first time that NR_109 exerted a crucial role in regulating the phenotype-remodeling and function of M2-like macrophages via a NR_109/FUBP1/c-Myc positive feedback loop. Thus, NR_109 has great translational potentials in the diagnosis, prognosis and immunotherapy of cancer.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD163 (CD163 Molecule) • IL4 (Interleukin 4)
|
MYC positive
11ms
A sub-population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL) (ICML 2023)
However, with larger numbers of DEL cases available in mRNA-based measurement cohorts, there was a statistically significant stratification for PFS (GSE117556: OS, p = 0.084, PFS, p = 0.031; GOYA: OS, p = 0.065, PFS, p = 0.047), suggesting that the following formula refines the current DEL definition and improves its prognostic value: Using a pan-immune protein-marker DSP panel, we identified that the T-cell immune regulators ICOS and 4-1BB were negatively correlated with M+2+6- percentage extent (r = −0.27, p = 0.0046; r = −0.22, p = 0.019, respectively), suggesting a potential role for ICOS or 4-1BB stimulatory therapeutics (e.g. feladilimab, utomilumab) in combination with chemotherapy for high M+2+6- cases. A simple mathematical formula for estimation of MYC+BCL2+BCL6- cells in DLBCL refines the DEL diagnosis, and could be of value in selecting high risk DLBCL for trials of novel agents. High M+2+6- DLBCL display unique T-cell infiltrates, and immunomodulation by ICOS and 4-1BB agonists could represent a therapeutic vulnerability for this high-risk subgroup.
Clinical • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)
|
BCL2 expression • MYC expression • MYC positive • MYC positive + BCL2 positive
|
feladilimab (GSK3359609) • utomilumab (PF-05082566)
11ms
Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma. (PubMed, Oncol Rep)
Pharmacological inhibition of EZH2 using EPZ005687 attenuated MB cell viability and reduced the expression of B7‑H3...Further, EZH2 silencing induced apoptosis and reduced colony‑forming ability in MB cells, whereas EZH2 inhibition in MYC‑amplified C17.2 neural stem cells induced G2/M phase arrest while downregulating B7‑H3 expression. Collectively, the current study positions EZH2 as a viable target for the future development of MB treatments and that targeting EZH2 in combination with B7‑H3 immunotherapy may be an effective treatment for halting MB progression.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • CD276 (CD276 Molecule) • MIR29A (MicroRNA 29a)
|
CD276 expression • MYC positive • EZH2 overexpression
|
EPZ005687
11ms
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. (PubMed, Nat Commun)
In turn, MYC increases expression of POLD1, forming a POLD1-MYC positive feedback loop to enhance the pro-carcinogenic effect of POLD1-MYC on BLCA. Overall, our study identifies POLD1 as a promotor of BCLA via a MYC driven mechanism and suggest its potential as biomarker for BLCA.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • POLD1 (DNA Polymerase Delta 1)
|
MYC expression • POLD1 mutation • MYC positive
12ms
Quantitative Diffusion-Weighted MRI of Neuroblastoma. (PubMed, Cancers (Basel))
This held true even within the first 120 days after the start of therapy: an increase in the ADC value corresponds to a probable response to therapy, while a decrease predicts progression. Minimal or no changes were seen in cases of stable disease.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYC expression • MYC positive
1year
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=22, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2024
Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive
|
Imbruvica (ibrutinib)
1year
A Case of Cardiac Lymphoma (ATS 2023)
The prognosis of PCL is poor and the only significant predictor for improved mortality is chemotherapy(3). Treatment is often delayed by confirmation of the diagnosis, but we present a unique case of cardiac lymphoma diagnosed by EBUS with biopsy of the metastatic disease and spared the patient from an invasive cardiac biopsy.
Clinical
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 positive • MYC positive
1year
Genomic features, evolutionary patterns, and minimal residual disease at surgical margins as novel prognostic/predictive biomarkers in locally advanced rectal cancer (AACR 2023)
Comprehensive genomic profiling helps identify multiple molecular prognostic and/or predictive biomarkers that could predict patients’ clinical outcomes to nCRT and TME and direct nCRT treatment regimen, thus facilitating more accurate prognostic estimation, a better balance between treatment efficacy and quality of life, and timely adjusted treatment decisions.
Minimal residual disease • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
|
KRAS mutation • MYC amplification • FBXW7 mutation • MYC positive
1year
Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. (PubMed, Mol Oncol)
Our work suggests that targeting G9a could prove to be a potential therapeutic avenue for Myc-driven liver cancer. This will increase our understanding of the underlying epigenetic mechanisms of aggressive tumor initiation and lead to improved therapeutic and diagnostic options for Myc-driven hepatic tumors.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDK9 (Cyclin Dependent Kinase 9)
|
MYC expression • MYC positive
1year
Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience. (PubMed, Curr Oncol)
A tendency of poor OS was seen in p53 patients in the non-GCB, GCB, and double expressors subgroups and poor PFS in p53 patients regardless of the subgrouping. In conclusion, our results suggest that p63 and p53 may represent potential additional prognostic biomarkers in DLBCL and may be included in the initial diagnostic work up of patients with DLBCL.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • TP63 (Tumor protein 63)
|
BCL2 expression • MYC expression • TP53 expression • MYC positive
1year
Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma. (PubMed, Yonago Acta Med)
A total of 110 patients diagnosed with DLBCL-NOS from 2012 to 2020 at Tottori University Hospital and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were included. The 2-year survival rates were 100%, 83.0%, and 47.1% for the groups 1, 2, and 3, respectively (P < 0.0001). We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL2 (Interleukin 2)
|
MYC expression • MYC positive • MYC negative
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine
1year
CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88 mutation: a case report and literature review (PubMed, Rinsho Ketsueki)
CD5- and CD10-positive DLBCL account for 0.5-1% of DLBCL cases and have a very poor disease prognosis. This is a rare case of CD5- and CD10-positive DLBCL with MYC and BCL2 expressions harboring MYD88 mutation.
Review • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
|
CD20 positive • MYD88 mutation • BCL2 expression • MYC expression • MYC positive • CD5 positive
1year
VENETOCLAX, CHIDAMIDE, AND DECITABINE AS A BRIDGING THERAPY IN RELAPSED/REFRACTORY T LYMPHOBLASTIC CELL LYMPHOMAS WITH LARGE MEDIASTINAL MASSES PRIOR TO CD7 CAR-T CELL THERAPY (EBMT 2023)
This clinical trial demonstrates promising efficacy of Venetoclax, Chidamide, and Decitabine as a bridging therapy in relapsed/refractory T-LBL with large mediastinal masses, although this not a randomized trial.
CAR T-Cell Therapy • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BCL6 (B-cell CLL/lymphoma 6) • CD7 (CD7 Molecule)
|
TP53 mutation • MYC positive
|
Venclexta (venetoclax) • decitabine • Epidaza (chidamide)
1year
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (clinicaltrials.gov)
P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • NOTCH2 (Notch 2) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • Chr del(17p) • CD20 positive • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
|
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)